Published by Josh White on 6th January 2023
(Sharecast News) - Clinical-stage biotherapeutics investor PureTech Health announced on Friday today that its digital medicine company Akili, which it founded, announced topline results of the 'STARS-ADHD-Adolescents' label expansion study evaluating the efficacy and safety of 'EndeavorRx', or 'AKL-T01' in adolescents aged 13 to 17 with attention-deficit hyperactivity disorder (ADHD).